• Cell Therapeutics Inc., of Seattle, said data on their Phase I study of its oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.
To continue reading subscribe now to BioWorld Today
